Mezavant Xl - Drug Insight, 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 27, 2018--The “Mezavant Xl - Drug Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
‘Mezavant Xl Drug Insight, 2018’ highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location.
The report covers the Global Market Assessment of the Mezavant Xl covering the historical global sales and also provides the Mezavant Xl sales estimation during the forecasted period (2018-2020).
The report also covers the patents information and market exclusivity data, route of synthesis, market competition, and API manufacturers by country. In addition to this, the report also provides the SWOT analysis for Mezavant Xl and emerging therapies in this space.
ScopeA review of the Mezavant Xl, based on information derived from company and industry-specific sources Product details on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification Coverage of the Drug Master Files and API Manufacturers by country Patent Expiry Timeline and Exclusivity Details Route of Synthesis of the API Forecasted Sales Figure from 2018-2020 Market competition and emerging therapies SWOT Analysis
Key Topics Covered
2. Mezavant Xl - OverviewProduct Description Route of Synthesis Mechanism of Action Pharmacology Pharmacodynamics Pharmacokinetics Adverse Reactions Regulatory Milestones by Region Deals and Partnerships
3. Product Details
4. Mezavant Xl Sales AssessmentHistorical Sales Forecasted Sales
5. Patent Details
6. Global API Manufacturers AssessmentActive Pharmaceutical Ingredient (API) Manufacturers by Country Active Pharmaceutical Ingredient (API) Manufacturers by Region
7. Market Competition
8. Emerging Therapies
8.1 Drug 1: Company 1Product Description Research and Development Product Development Activities
9. SWOT Analysis
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/c3bdvs/mezavant_xl?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181227005149/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Gastrointestinal Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 12/27/2018 05:58 AM/DISC: 12/27/2018 05:58 AM